STUDYID,USUBJID,SUBJID,SITEID,AGE,AGEU,SEX,RACE,RACEN,COUNTRY,COUNTRYC,REGION,REGIONN,REGNGR1,REGNGR1N,REGNGR2,REGNGR2N,SAFFL,ITTFL,HITTFL,TEVLFL,CAEVLFL,ARM,TRTP,TRTPN,TRTA,TRTAN,HENT1ST,HENT1STN,RES10X,STRATA1,STRATA2,PARAM,PARAMCD,PARAMN,AVAL,STARTDT,ADT,CNSR,EVNTDESC
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,14.685831622176591,2010-11-01,2012-01-21,0.0,DEATH
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,14.685831622176591,2010-11-01,2012-01-21,0.0,DEATH
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months),TIME2DTH,1.0,14.685831622176591,2010-11-01,2012-01-21,0.0,DEATH
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.37782340862423,2011-05-03,2012-01-12,0.0,DEATH
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.37782340862423,2011-05-03,2012-01-12,0.0,DEATH
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months),TIME2DTH,1.0,8.37782340862423,2011-05-03,2012-01-12,0.0,DEATH
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,15.770020533880903,2011-05-10,2012-08-31,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,15.770020533880903,2011-05-10,2012-08-31,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months),TIME2DTH,1.0,15.770020533880903,2011-05-10,2012-08-31,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.2299794661190965,2011-11-01,2011-11-07,0.0,DEATH
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.2299794661190965,2011-11-01,2011-11-07,0.0,DEATH
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.2299794661190965,2011-11-01,2011-11-07,0.0,DEATH
CO-101-001,CO-101-001-001-010,01001010,001,65.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.073921971252567,2012-02-06,2012-06-08,0.0,DEATH
CO-101-001,CO-101-001-001-010,01001010,001,65.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.073921971252567,2012-02-06,2012-06-08,0.0,DEATH
CO-101-001,CO-101-001-001-010,01001010,001,65.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.073921971252567,2012-02-06,2012-06-08,0.0,DEATH
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.772073921971252,2011-01-20,2011-10-13,0.0,DEATH
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.772073921971252,2011-01-20,2011-10-13,0.0,DEATH
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months),TIME2DTH,1.0,8.772073921971252,2011-01-20,2011-10-13,0.0,DEATH
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.878850102669405,2011-05-26,2012-06-20,0.0,DEATH
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.878850102669405,2011-05-26,2012-06-20,0.0,DEATH
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,12.878850102669405,2011-05-26,2012-06-20,0.0,DEATH
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.706365503080082,2011-06-06,2012-02-25,0.0,DEATH
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.706365503080082,2011-06-06,2012-02-25,0.0,DEATH
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months),TIME2DTH,1.0,8.706365503080082,2011-06-06,2012-02-25,0.0,DEATH
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.162217659137577,2012-01-03,2012-08-07,0.0,DEATH
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.162217659137577,2012-01-03,2012-08-07,0.0,DEATH
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months),TIME2DTH,1.0,7.162217659137577,2012-01-03,2012-08-07,0.0,DEATH
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.698151950718686,2011-03-01,2011-07-21,0.0,DEATH
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.698151950718686,2011-03-01,2011-07-21,0.0,DEATH
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.698151950718686,2011-03-01,2011-07-21,0.0,DEATH
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.217659137577002,2011-03-30,2012-02-03,0.0,DEATH
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.217659137577002,2011-03-30,2012-02-03,0.0,DEATH
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,1.0,1.0,Time to Death (months),TIME2DTH,1.0,10.217659137577002,2011-03-30,2012-02-03,0.0,DEATH
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.7084188911704312,2011-03-11,2011-05-01,0.0,DEATH
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.7084188911704312,2011-03-11,2011-05-01,0.0,DEATH
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.7084188911704312,2011-03-11,2011-05-01,0.0,DEATH
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.675564681724846,2011-06-06,2011-07-26,0.0,DEATH
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.675564681724846,2011-06-06,2011-07-26,0.0,DEATH
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.675564681724846,2011-06-06,2011-07-26,0.0,DEATH
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.885010266940451,2011-06-20,2012-02-14,0.0,DEATH
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.885010266940451,2011-06-20,2012-02-14,0.0,DEATH
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,1.0,1.0,Time to Death (months),TIME2DTH,1.0,7.885010266940451,2011-06-20,2012-02-14,0.0,DEATH
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,13.86447638603696,2011-08-29,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,13.86447638603696,2011-08-29,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,13.86447638603696,2011-08-29,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.238193018480493,2012-01-24,2012-05-31,0.0,DEATH
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.238193018480493,2012-01-24,2012-05-31,0.0,DEATH
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.238193018480493,2012-01-24,2012-05-31,0.0,DEATH
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.8439425051334704,2012-02-28,2012-06-23,0.0,DEATH
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.8439425051334704,2012-02-28,2012-06-23,0.0,DEATH
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.8439425051334704,2012-02-28,2012-06-23,0.0,DEATH
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,13.831622176591376,2011-02-02,2012-03-28,0.0,DEATH
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,13.831622176591376,2011-02-02,2012-03-28,0.0,DEATH
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months),TIME2DTH,1.0,13.831622176591376,2011-02-02,2012-03-28,0.0,DEATH
CO-101-001,CO-101-001-009-002,01009002,009,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,19.581108829568787,2011-03-01,2012-10-16,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-009-002,01009002,009,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,19.581108829568787,2011-03-01,2012-10-16,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-009-002,01009002,009,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,40,0.0,1.0,Time to Death (months),TIME2DTH,1.0,19.581108829568787,2011-03-01,2012-10-16,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,23.917864476386036,2010-11-09,2012-11-05,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,23.917864476386036,2010-11-09,2012-11-05,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,0.0,1.0,Time to Death (months),TIME2DTH,1.0,23.917864476386036,2010-11-09,2012-11-05,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.936344969199178,2010-12-13,2011-09-10,0.0,DEATH
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.936344969199178,2010-12-13,2011-09-10,0.0,DEATH
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.936344969199178,2010-12-13,2011-09-10,0.0,DEATH
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.6036960985626285,2011-01-26,2011-08-14,0.0,DEATH
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.6036960985626285,2011-01-26,2011-08-14,0.0,DEATH
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,6.6036960985626285,2011-01-26,2011-08-14,0.0,DEATH
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.9712525667351128,2011-09-05,2011-11-03,0.0,DEATH
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.9712525667351128,2011-09-05,2011-11-03,0.0,DEATH
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.9712525667351128,2011-09-05,2011-11-03,0.0,DEATH
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.386036960985626,2011-09-21,2012-10-01,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.386036960985626,2011-09-21,2012-10-01,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,12.386036960985626,2011-09-21,2012-10-01,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.232032854209445,2012-01-17,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.232032854209445,2012-01-17,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months),TIME2DTH,1.0,9.232032854209445,2012-01-17,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.9527720739219713,2010-08-04,2010-09-01,0.0,DEATH
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.9527720739219713,2010-08-04,2010-09-01,0.0,DEATH
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.9527720739219713,2010-08-04,2010-09-01,0.0,DEATH
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.13347022587269,2012-01-12,2012-10-15,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.13347022587269,2012-01-12,2012-10-15,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,9.13347022587269,2012-01-12,2012-10-15,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.8069815195071868,2011-02-01,2011-03-27,0.0,DEATH
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.8069815195071868,2011-02-01,2011-03-27,0.0,DEATH
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.8069815195071868,2011-02-01,2011-03-27,0.0,DEATH
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,19.613963039014372,2011-01-12,2012-08-30,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,19.613963039014372,2011-01-12,2012-08-30,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,19.613963039014372,2011-01-12,2012-08-30,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-019-002,01019002,019,59.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.782340862422998,2011-01-26,2011-07-20,0.0,DEATH
CO-101-001,CO-101-001-019-002,01019002,019,59.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.782340862422998,2011-01-26,2011-07-20,0.0,DEATH
CO-101-001,CO-101-001-019-002,01019002,019,59.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,40,0.0,1.0,Time to Death (months),TIME2DTH,1.0,5.782340862422998,2011-01-26,2011-07-20,0.0,DEATH
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.848049281314168,2011-08-16,2012-02-09,0.0,DEATH
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.848049281314168,2011-08-16,2012-02-09,0.0,DEATH
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.848049281314168,2011-08-16,2012-02-09,0.0,DEATH
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.336755646817249,2011-08-16,2011-12-25,0.0,DEATH
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.336755646817249,2011-08-16,2011-12-25,0.0,DEATH
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.336755646817249,2011-08-16,2011-12-25,0.0,DEATH
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.958932238193018,2011-02-10,2012-02-08,0.0,DEATH
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.958932238193018,2011-02-10,2012-02-08,0.0,DEATH
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months),TIME2DTH,1.0,11.958932238193018,2011-02-10,2012-02-08,0.0,DEATH
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.28952772073922,2011-07-25,2012-01-01,0.0,DEATH
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.28952772073922,2011-07-25,2012-01-01,0.0,DEATH
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.28952772073922,2011-07-25,2012-01-01,0.0,DEATH
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.344969199178644,2011-10-26,2012-07-05,0.0,DEATH
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.344969199178644,2011-10-26,2012-07-05,0.0,DEATH
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.344969199178644,2011-10-26,2012-07-05,0.0,DEATH
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,55,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.574948665297741,2011-11-21,2012-08-07,0.0,DEATH
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,55,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.574948665297741,2011-11-21,2012-08-07,0.0,DEATH
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,55,0.0,1.0,Time to Death (months),TIME2DTH,1.0,8.574948665297741,2011-11-21,2012-08-07,0.0,DEATH
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.250513347022586,2010-12-23,2011-10-30,0.0,DEATH
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.250513347022586,2010-12-23,2011-10-30,0.0,DEATH
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months),TIME2DTH,1.0,10.250513347022586,2010-12-23,2011-10-30,0.0,DEATH
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.486652977412731,2011-02-24,2011-08-09,0.0,DEATH
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.486652977412731,2011-02-24,2011-08-09,0.0,DEATH
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.486652977412731,2011-02-24,2011-08-09,0.0,DEATH
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.059548254620124,2011-02-24,2011-07-27,0.0,DEATH
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.059548254620124,2011-02-24,2011-07-27,0.0,DEATH
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.059548254620124,2011-02-24,2011-07-27,0.0,DEATH
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,55,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,17.51129363449692,2011-05-23,2012-11-05,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,55,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,17.51129363449692,2011-05-23,2012-11-05,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,55,1.0,1.0,Time to Death (months),TIME2DTH,1.0,17.51129363449692,2011-05-23,2012-11-05,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,15.605749486652977,2011-07-21,2012-11-06,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,15.605749486652977,2011-07-21,2012-11-06,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,15.605749486652977,2011-07-21,2012-11-06,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.256673511293634,2012-01-02,2012-06-09,0.0,DEATH
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.256673511293634,2012-01-02,2012-06-09,0.0,DEATH
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.256673511293634,2012-01-02,2012-06-09,0.0,DEATH
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.0882956878850103,2011-01-12,2011-04-15,0.0,DEATH
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.0882956878850103,2011-01-12,2011-04-15,0.0,DEATH
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.0882956878850103,2011-01-12,2011-04-15,0.0,DEATH
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.4271047227926078,2011-03-30,2011-04-11,0.0,DEATH
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.4271047227926078,2011-03-30,2011-04-11,0.0,DEATH
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,50,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.4271047227926078,2011-03-30,2011-04-11,0.0,DEATH
CO-101-001,CO-101-001-024-004,01024004,024,64.0,YEARS,F,OTHER,99.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.4271047227926078,2011-12-01,2011-12-13,0.0,DEATH
CO-101-001,CO-101-001-024-004,01024004,024,64.0,YEARS,F,OTHER,99.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.4271047227926078,2011-12-01,2011-12-13,0.0,DEATH
CO-101-001,CO-101-001-024-004,01024004,024,64.0,YEARS,F,OTHER,99.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.4271047227926078,2011-12-01,2011-12-13,0.0,DEATH
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.308008213552362,2011-01-17,2011-07-27,0.0,DEATH
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.308008213552362,2011-01-17,2011-07-27,0.0,DEATH
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,6.308008213552362,2011-01-17,2011-07-27,0.0,DEATH
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.919917864476386,2011-02-28,2011-03-27,0.0,DEATH
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.919917864476386,2011-02-28,2011-03-27,0.0,DEATH
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.919917864476386,2011-02-28,2011-03-27,0.0,DEATH
CO-101-001,CO-101-001-025-003,01025003,025,66.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.32854209445585214,2011-04-05,2011-04-14,0.0,DEATH
CO-101-001,CO-101-001-025-003,01025003,025,66.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.32854209445585214,2011-04-05,2011-04-14,0.0,DEATH
CO-101-001,CO-101-001-025-003,01025003,025,66.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.32854209445585214,2011-04-05,2011-04-14,0.0,DEATH
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.252566735112936,2010-12-14,2011-03-22,0.0,DEATH
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.252566735112936,2010-12-14,2011-03-22,0.0,DEATH
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,0.0,1.0,Time to Death (months),TIME2DTH,1.0,3.252566735112936,2010-12-14,2011-03-22,0.0,DEATH
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.965092402464066,2012-03-27,2012-10-24,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.965092402464066,2012-03-27,2012-10-24,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months),TIME2DTH,1.0,6.965092402464066,2012-03-27,2012-10-24,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.1683778234086244,2012-01-02,2012-03-07,0.0,DEATH
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.1683778234086244,2012-01-02,2012-03-07,0.0,DEATH
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,90,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.1683778234086244,2012-01-02,2012-03-07,0.0,DEATH
CO-101-001,CO-101-001-031-001,01031001,031,66.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,0.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,13.60164271047228,2011-04-13,2012-05-30,0.0,DEATH
CO-101-001,CO-101-001-031-001,01031001,031,66.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,0.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,13.60164271047228,2011-04-13,2012-05-30,0.0,DEATH
CO-101-001,CO-101-001-031-001,01031001,031,66.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,0.0,3.0,Time to Death (months),TIME2DTH,1.0,13.60164271047228,2011-04-13,2012-05-30,0.0,DEATH
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.7412731006160165,2012-01-23,2012-03-15,0.0,DEATH
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.7412731006160165,2012-01-23,2012-03-15,0.0,DEATH
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25,1.0,3.0,Time to Death (months),TIME2DTH,1.0,1.7412731006160165,2012-01-23,2012-03-15,0.0,DEATH
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,55,0.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.714579055441478,2011-09-20,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,55,0.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.714579055441478,2011-09-20,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,55,0.0,3.0,Time to Death (months),TIME2DTH,1.0,12.714579055441478,2011-09-20,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.527720739219713,2011-05-09,2012-02-22,0.0,DEATH
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.527720739219713,2011-05-09,2012-02-22,0.0,DEATH
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,3.0,Time to Death (months),TIME2DTH,1.0,9.527720739219713,2011-05-09,2012-02-22,0.0,DEATH
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.6652977412731005,2011-08-18,2012-01-06,0.0,DEATH
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.6652977412731005,2011-08-18,2012-01-06,0.0,DEATH
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,3.0,Time to Death (months),TIME2DTH,1.0,4.6652977412731005,2011-08-18,2012-01-06,0.0,DEATH
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.772073921971252,2011-08-31,2012-05-23,0.0,DEATH
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.772073921971252,2011-08-31,2012-05-23,0.0,DEATH
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,3.0,Time to Death (months),TIME2DTH,1.0,8.772073921971252,2011-08-31,2012-05-23,0.0,DEATH
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.515400410677618,2012-02-10,2012-05-26,0.0,DEATH
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.515400410677618,2012-02-10,2012-05-26,0.0,DEATH
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,3.0,Time to Death (months),TIME2DTH,1.0,3.515400410677618,2012-02-10,2012-05-26,0.0,DEATH
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.1827515400410678,2011-05-30,2011-07-04,0.0,DEATH
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.1827515400410678,2011-05-30,2011-07-04,0.0,DEATH
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,3.0,Time to Death (months),TIME2DTH,1.0,1.1827515400410678,2011-05-30,2011-07-04,0.0,DEATH
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,0.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.7885010266940452,2011-07-12,2011-08-04,0.0,DEATH
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,0.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.7885010266940452,2011-07-12,2011-08-04,0.0,DEATH
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,0.0,3.0,Time to Death (months),TIME2DTH,1.0,0.7885010266940452,2011-07-12,2011-08-04,0.0,DEATH
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.32854209445585214,2011-11-01,2011-11-10,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.32854209445585214,2011-11-01,2011-11-10,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,3.0,Time to Death (months),TIME2DTH,1.0,0.32854209445585214,2011-11-01,2011-11-10,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,0.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.519507186858316,2011-08-31,2012-02-14,0.0,DEATH
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,0.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.519507186858316,2011-08-31,2012-02-14,0.0,DEATH
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,0.0,3.0,Time to Death (months),TIME2DTH,1.0,5.519507186858316,2011-08-31,2012-02-14,0.0,DEATH
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.4928131416837782,2011-08-31,2011-09-14,0.0,DEATH
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.4928131416837782,2011-08-31,2011-09-14,0.0,DEATH
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,3.0,Time to Death (months),TIME2DTH,1.0,0.4928131416837782,2011-08-31,2011-09-14,0.0,DEATH
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.057494866529774,2011-09-16,2012-09-16,0.0,DEATH
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.057494866529774,2011-09-16,2012-09-16,0.0,DEATH
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,3.0,Time to Death (months),TIME2DTH,1.0,12.057494866529774,2011-09-16,2012-09-16,0.0,DEATH
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,17.642710472279262,2010-12-22,2012-06-10,0.0,DEATH
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,17.642710472279262,2010-12-22,2012-06-10,0.0,DEATH
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months),TIME2DTH,1.0,17.642710472279262,2010-12-22,2012-06-10,0.0,DEATH
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.2197125256673513,2011-06-28,2011-10-03,0.0,DEATH
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.2197125256673513,2011-06-28,2011-10-03,0.0,DEATH
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.2197125256673513,2011-06-28,2011-10-03,0.0,DEATH
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.5770020533880904,2011-09-14,2011-10-31,0.0,DEATH
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.5770020533880904,2011-09-14,2011-10-31,0.0,DEATH
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.5770020533880904,2011-09-14,2011-10-31,0.0,DEATH
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.4496919917864477,2012-01-04,2012-04-17,0.0,DEATH
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.4496919917864477,2012-01-04,2012-04-17,0.0,DEATH
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.4496919917864477,2012-01-04,2012-04-17,0.0,DEATH
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.975359342915811,2011-04-04,2011-08-02,0.0,DEATH
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.975359342915811,2011-04-04,2011-08-02,0.0,DEATH
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.975359342915811,2011-04-04,2011-08-02,0.0,DEATH
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.7453798767967146,2011-05-16,2011-09-06,0.0,DEATH
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.7453798767967146,2011-05-16,2011-09-06,0.0,DEATH
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months),TIME2DTH,1.0,3.7453798767967146,2011-05-16,2011-09-06,0.0,DEATH
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.5564681724846,2011-05-16,2011-12-31,0.0,DEATH
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.5564681724846,2011-05-16,2011-12-31,0.0,DEATH
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,7.5564681724846,2011-05-16,2011-12-31,0.0,DEATH
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.0184804928131417,2011-10-18,2011-11-17,0.0,DEATH
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.0184804928131417,2011-10-18,2011-11-17,0.0,DEATH
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.0184804928131417,2011-10-18,2011-11-17,0.0,DEATH
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.560574948665298,2012-01-09,2012-10-25,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.560574948665298,2012-01-09,2012-10-25,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months),TIME2DTH,1.0,9.560574948665298,2012-01-09,2012-10-25,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.628336755646817,2012-01-16,2012-04-04,0.0,DEATH
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.628336755646817,2012-01-16,2012-04-04,0.0,DEATH
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.628336755646817,2012-01-16,2012-04-04,0.0,DEATH
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.154004106776181,2012-01-23,2012-04-27,0.0,DEATH
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.154004106776181,2012-01-23,2012-04-27,0.0,DEATH
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.154004106776181,2012-01-23,2012-04-27,0.0,DEATH
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,0.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.570841889117043,2011-05-04,2011-11-19,0.0,DEATH
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,0.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.570841889117043,2011-05-04,2011-11-19,0.0,DEATH
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,0.0,3.0,Time to Death (months),TIME2DTH,1.0,6.570841889117043,2011-05-04,2011-11-19,0.0,DEATH
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,14.817248459958932,2010-11-12,2012-02-05,0.0,DEATH
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,14.817248459958932,2010-11-12,2012-02-05,0.0,DEATH
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months),TIME2DTH,1.0,14.817248459958932,2010-11-12,2012-02-05,0.0,DEATH
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.679671457905544,2011-01-31,2011-05-22,0.0,DEATH
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.679671457905544,2011-01-31,2011-05-22,0.0,DEATH
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.679671457905544,2011-01-31,2011-05-22,0.0,DEATH
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.147843942505133,2011-04-04,2011-12-07,0.0,DEATH
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.147843942505133,2011-04-04,2011-12-07,0.0,DEATH
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Australia/South America,4.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.147843942505133,2011-04-04,2011-12-07,0.0,DEATH
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,95,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.6036960985626285,2011-09-20,2012-04-07,0.0,DEATH
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,95,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.6036960985626285,2011-09-20,2012-04-07,0.0,DEATH
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,95,1.0,3.0,Time to Death (months),TIME2DTH,1.0,6.6036960985626285,2011-09-20,2012-04-07,0.0,DEATH
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.431211498973306,2011-06-29,2011-09-10,0.0,DEATH
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.431211498973306,2011-06-29,2011-09-10,0.0,DEATH
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,3.0,Time to Death (months),TIME2DTH,1.0,2.431211498973306,2011-06-29,2011-09-10,0.0,DEATH
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.482546201232033,2011-10-20,2012-02-02,0.0,DEATH
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.482546201232033,2011-10-20,2012-02-02,0.0,DEATH
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,3.0,Time to Death (months),TIME2DTH,1.0,3.482546201232033,2011-10-20,2012-02-02,0.0,DEATH
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,3.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.628336755646817,2011-08-08,2011-10-26,0.0,DEATH
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,3.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.628336755646817,2011-08-08,2011-10-26,0.0,DEATH
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Australia/South America,4.0,South America,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,3.0,Time to Death (months),TIME2DTH,1.0,2.628336755646817,2011-08-08,2011-10-26,0.0,DEATH
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.5626283367556466,2011-01-21,2011-04-08,0.0,DEATH
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.5626283367556466,2011-01-21,2011-04-08,0.0,DEATH
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.5626283367556466,2011-01-21,2011-04-08,0.0,DEATH
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.15605749486653,2011-01-24,2012-01-28,0.0,DEATH
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.15605749486653,2011-01-24,2012-01-28,0.0,DEATH
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months),TIME2DTH,1.0,12.15605749486653,2011-01-24,2012-01-28,0.0,DEATH
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.4496919917864477,2012-01-02,2012-04-15,0.0,DEATH
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.4496919917864477,2012-01-02,2012-04-15,0.0,DEATH
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.4496919917864477,2012-01-02,2012-04-15,0.0,DEATH
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,13.437371663244353,2011-03-02,2012-04-13,0.0,DEATH
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,13.437371663244353,2011-03-02,2012-04-13,0.0,DEATH
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months),TIME2DTH,1.0,13.437371663244353,2011-03-02,2012-04-13,0.0,DEATH
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.186858316221766,2011-04-19,2011-07-24,0.0,DEATH
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.186858316221766,2011-04-19,2011-07-24,0.0,DEATH
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,0.0,1.0,Time to Death (months),TIME2DTH,1.0,3.186858316221766,2011-04-19,2011-07-24,0.0,DEATH
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.11088295687885,2011-03-31,2011-10-02,0.0,DEATH
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.11088295687885,2011-03-31,2011-10-02,0.0,DEATH
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months),TIME2DTH,1.0,6.11088295687885,2011-03-31,2011-10-02,0.0,DEATH
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.078028747433265,2011-06-01,2011-12-02,0.0,DEATH
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.078028747433265,2011-06-01,2011-12-02,0.0,DEATH
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months),TIME2DTH,1.0,6.078028747433265,2011-06-01,2011-12-02,0.0,DEATH
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.632443531827516,2011-08-02,2011-12-20,0.0,DEATH
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.632443531827516,2011-08-02,2011-12-20,0.0,DEATH
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.632443531827516,2011-08-02,2011-12-20,0.0,DEATH
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,85,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.529774127310062,2012-03-20,2012-06-04,0.0,DEATH
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,85,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.529774127310062,2012-03-20,2012-06-04,0.0,DEATH
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,85,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.529774127310062,2012-03-20,2012-06-04,0.0,DEATH
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.092402464065708,2011-05-11,2011-10-12,0.0,DEATH
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.092402464065708,2011-05-11,2011-10-12,0.0,DEATH
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.092402464065708,2011-05-11,2011-10-12,0.0,DEATH
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.77618069815195,2011-11-30,2012-10-22,0.0,DEATH
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.77618069815195,2011-11-30,2012-10-22,0.0,DEATH
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months),TIME2DTH,1.0,10.77618069815195,2011-11-30,2012-10-22,0.0,DEATH
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.004106776180698,2010-12-14,2011-02-12,0.0,DEATH
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.004106776180698,2010-12-14,2011-02-12,0.0,DEATH
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months),TIME2DTH,1.0,2.004106776180698,2010-12-14,2011-02-12,0.0,DEATH
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.681724845995893,2010-12-14,2012-01-03,0.0,DEATH
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.681724845995893,2010-12-14,2012-01-03,0.0,DEATH
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months),TIME2DTH,1.0,12.681724845995893,2010-12-14,2012-01-03,0.0,DEATH
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,20.041067761806982,2011-02-21,2012-10-22,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,20.041067761806982,2011-02-21,2012-10-22,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months),TIME2DTH,1.0,20.041067761806982,2011-02-21,2012-10-22,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.457905544147844,2011-02-24,2011-10-08,0.0,DEATH
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.457905544147844,2011-02-24,2011-10-08,0.0,DEATH
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,7.457905544147844,2011-02-24,2011-10-08,0.0,DEATH
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.3347022587269,2011-06-16,2012-05-25,0.0,DEATH
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.3347022587269,2011-06-16,2012-05-25,0.0,DEATH
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months),TIME2DTH,1.0,11.3347022587269,2011-06-16,2012-05-25,0.0,DEATH
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.874743326488707,2011-11-22,2012-10-17,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.874743326488707,2011-11-22,2012-10-17,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months),TIME2DTH,1.0,10.874743326488707,2011-11-22,2012-10-17,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.7084188911704312,2011-12-07,2012-01-27,0.0,DEATH
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.7084188911704312,2011-12-07,2012-01-27,0.0,DEATH
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months),TIME2DTH,1.0,1.7084188911704312,2011-12-07,2012-01-27,0.0,DEATH
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.64476386036961,2011-12-14,2012-11-01,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.64476386036961,2011-12-14,2012-11-01,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15,0.0,1.0,Time to Death (months),TIME2DTH,1.0,10.64476386036961,2011-12-14,2012-11-01,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.351129363449692,2012-01-11,2012-04-21,0.0,DEATH
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.351129363449692,2012-01-11,2012-04-21,0.0,DEATH
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.351129363449692,2012-01-11,2012-04-21,0.0,DEATH
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.2669404517453797,2012-04-04,2012-06-11,0.0,DEATH
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.2669404517453797,2012-04-04,2012-06-11,0.0,DEATH
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.2669404517453797,2012-04-04,2012-06-11,0.0,DEATH
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,15.277207392197125,2010-08-05,2011-11-12,0.0,DEATH
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,15.277207392197125,2010-08-05,2011-11-12,0.0,DEATH
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,0.0,1.0,Time to Death (months),TIME2DTH,1.0,15.277207392197125,2010-08-05,2011-11-12,0.0,DEATH
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.7453798767967146,2010-09-08,2010-12-30,0.0,DEATH
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.7453798767967146,2010-09-08,2010-12-30,0.0,DEATH
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months),TIME2DTH,1.0,3.7453798767967146,2010-09-08,2010-12-30,0.0,DEATH
CO-101-001,CO-101-001-055-005,01055005,055,37.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.402464065708419,2010-09-28,2011-02-08,0.0,DEATH
CO-101-001,CO-101-001-055-005,01055005,055,37.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.402464065708419,2010-09-28,2011-02-08,0.0,DEATH
CO-101-001,CO-101-001-055-005,01055005,055,37.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.402464065708419,2010-09-28,2011-02-08,0.0,DEATH
CO-101-001,CO-101-001-055-006,01055006,055,43.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,24.213552361396303,2010-10-18,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-055-006,01055006,055,43.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,24.213552361396303,2010-10-18,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-055-006,01055006,055,43.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,0.0,1.0,Time to Death (months),TIME2DTH,1.0,24.213552361396303,2010-10-18,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.351129363449692,2011-02-16,2011-05-28,0.0,DEATH
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.351129363449692,2011-02-16,2011-05-28,0.0,DEATH
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.351129363449692,2011-02-16,2011-05-28,0.0,DEATH
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,100,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.030800821355236,2011-05-09,2011-12-08,0.0,DEATH
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,100,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.030800821355236,2011-05-09,2011-12-08,0.0,DEATH
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,100,0.0,1.0,Time to Death (months),TIME2DTH,1.0,7.030800821355236,2011-05-09,2011-12-08,0.0,DEATH
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.9281314168377826,2011-04-26,2011-09-22,0.0,DEATH
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.9281314168377826,2011-04-26,2011-09-22,0.0,DEATH
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.9281314168377826,2011-04-26,2011-09-22,0.0,DEATH
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.139630390143737,2011-05-17,2011-09-19,0.0,DEATH
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.139630390143737,2011-05-17,2011-09-19,0.0,DEATH
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months),TIME2DTH,1.0,4.139630390143737,2011-05-17,2011-09-19,0.0,DEATH
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.420944558521561,2011-07-12,2011-12-23,0.0,DEATH
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.420944558521561,2011-07-12,2011-12-23,0.0,DEATH
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months),TIME2DTH,1.0,5.420944558521561,2011-07-12,2011-12-23,0.0,DEATH
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.172484599589322,2011-11-02,2012-03-07,0.0,DEATH
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.172484599589322,2011-11-02,2012-03-07,0.0,DEATH
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,0.0,1.0,Time to Death (months),TIME2DTH,1.0,4.172484599589322,2011-11-02,2012-03-07,0.0,DEATH
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.46611909650924,2011-04-21,2012-04-03,0.0,DEATH
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.46611909650924,2011-04-21,2012-04-03,0.0,DEATH
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7,0.0,1.0,Time to Death (months),TIME2DTH,1.0,11.46611909650924,2011-04-21,2012-04-03,0.0,DEATH
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.388090349075975,2011-05-05,2011-10-15,0.0,DEATH
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.388090349075975,2011-05-05,2011-10-15,0.0,DEATH
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,0.0,1.0,Time to Death (months),TIME2DTH,1.0,5.388090349075975,2011-05-05,2011-10-15,0.0,DEATH
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.09034907597536,2011-07-13,2012-07-14,0.0,DEATH
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.09034907597536,2011-07-13,2012-07-14,0.0,DEATH
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,12.09034907597536,2011-07-13,2012-07-14,0.0,DEATH
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.815195071868583,2011-09-30,2012-03-24,0.0,DEATH
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.815195071868583,2011-09-30,2012-03-24,0.0,DEATH
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.815195071868583,2011-09-30,2012-03-24,0.0,DEATH
CO-101-001,CO-101-001-060-008,01060008,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.3942505133470226,2011-10-19,2011-10-30,0.0,DEATH
CO-101-001,CO-101-001-060-008,01060008,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.3942505133470226,2011-10-19,2011-10-30,0.0,DEATH
CO-101-001,CO-101-001-060-008,01060008,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,0.0,1.0,Time to Death (months),TIME2DTH,1.0,0.3942505133470226,2011-10-19,2011-10-30,0.0,DEATH
CO-101-001,CO-101-001-060-009,01060009,060,77.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.909650924024641,2012-02-14,2012-06-11,0.0,DEATH
CO-101-001,CO-101-001-060-009,01060009,060,77.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.909650924024641,2012-02-14,2012-06-11,0.0,DEATH
CO-101-001,CO-101-001-060-009,01060009,060,77.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,0.0,1.0,Time to Death (months),TIME2DTH,1.0,3.909650924024641,2012-02-14,2012-06-11,0.0,DEATH
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.227926078028747,2012-03-05,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.227926078028747,2012-03-05,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,0.0,1.0,Time to Death (months),TIME2DTH,1.0,7.227926078028747,2012-03-05,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.8870636550308009,2011-05-03,2011-05-29,0.0,DEATH
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.8870636550308009,2011-05-03,2011-05-29,0.0,DEATH
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.8870636550308009,2011-05-03,2011-05-29,0.0,DEATH
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.5626283367556466,2011-08-22,2011-11-07,0.0,DEATH
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.5626283367556466,2011-08-22,2011-11-07,0.0,DEATH
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.5626283367556466,2011-08-22,2011-11-07,0.0,DEATH
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.158110882956879,2011-11-09,2012-04-13,0.0,DEATH
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.158110882956879,2011-11-09,2012-04-13,0.0,DEATH
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.158110882956879,2011-11-09,2012-04-13,0.0,DEATH
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,98,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.170431211498974,2011-11-18,2012-10-22,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,98,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.170431211498974,2011-11-18,2012-10-22,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,98,1.0,1.0,Time to Death (months),TIME2DTH,1.0,11.170431211498974,2011-11-18,2012-10-22,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.260780287474333,2011-11-25,2012-07-02,0.0,DEATH
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.260780287474333,2011-11-25,2012-07-02,0.0,DEATH
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,0.0,1.0,Time to Death (months),TIME2DTH,1.0,7.260780287474333,2011-11-25,2012-07-02,0.0,DEATH
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.5811088295687883,2012-01-13,2012-04-30,0.0,DEATH
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.5811088295687883,2012-01-13,2012-04-30,0.0,DEATH
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.5811088295687883,2012-01-13,2012-04-30,0.0,DEATH
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.195071868583162,2012-01-31,2012-09-05,0.0,DEATH
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.195071868583162,2012-01-31,2012-09-05,0.0,DEATH
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months),TIME2DTH,1.0,7.195071868583162,2012-01-31,2012-09-05,0.0,DEATH
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.4640657084188913,2012-02-06,2012-04-20,0.0,DEATH
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.4640657084188913,2012-02-06,2012-04-20,0.0,DEATH
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.4640657084188913,2012-02-06,2012-04-20,0.0,DEATH
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.5564681724846,2012-02-24,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.5564681724846,2012-02-24,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months),TIME2DTH,1.0,7.5564681724846,2012-02-24,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,45,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.919917864476386,2012-02-28,2012-03-26,0.0,DEATH
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,45,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.919917864476386,2012-02-28,2012-03-26,0.0,DEATH
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,45,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.919917864476386,2012-02-28,2012-03-26,0.0,DEATH
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.9568788501026693,2011-05-31,2011-08-28,0.0,DEATH
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.9568788501026693,2011-05-31,2011-08-28,0.0,DEATH
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.9568788501026693,2011-05-31,2011-08-28,0.0,DEATH
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.215605749486653,2011-12-09,2012-01-14,0.0,DEATH
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.215605749486653,2011-12-09,2012-01-14,0.0,DEATH
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.215605749486653,2011-12-09,2012-01-14,0.0,DEATH
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,16.82135523613963,2010-09-20,2012-02-13,0.0,DEATH
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,16.82135523613963,2010-09-20,2012-02-13,0.0,DEATH
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,0.0,1.0,Time to Death (months),TIME2DTH,1.0,16.82135523613963,2010-09-20,2012-02-13,0.0,DEATH
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.053388090349076,2010-11-05,2011-09-06,0.0,DEATH
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.053388090349076,2010-11-05,2011-09-06,0.0,DEATH
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months),TIME2DTH,1.0,10.053388090349076,2010-11-05,2011-09-06,0.0,DEATH
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.223819301848049,2010-11-23,2011-04-30,0.0,DEATH
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.223819301848049,2010-11-23,2011-04-30,0.0,DEATH
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months),TIME2DTH,1.0,5.223819301848049,2010-11-23,2011-04-30,0.0,DEATH
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.88911704312115,2011-06-06,2012-04-01,0.0,DEATH
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.88911704312115,2011-06-06,2012-04-01,0.0,DEATH
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,9.88911704312115,2011-06-06,2012-04-01,0.0,DEATH
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.903490759753593,2011-08-12,2012-05-08,0.0,DEATH
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.903490759753593,2011-08-12,2012-05-08,0.0,DEATH
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.903490759753593,2011-08-12,2012-05-08,0.0,DEATH
CO-101-001,CO-101-001-065-002,01065002,065,59.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.008213552361396,2011-04-28,2011-08-27,0.0,DEATH
CO-101-001,CO-101-001-065-002,01065002,065,59.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.008213552361396,2011-04-28,2011-08-27,0.0,DEATH
CO-101-001,CO-101-001-065-002,01065002,065,59.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.008213552361396,2011-04-28,2011-08-27,0.0,DEATH
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.529774127310062,2011-05-31,2011-08-15,0.0,DEATH
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.529774127310062,2011-05-31,2011-08-15,0.0,DEATH
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.529774127310062,2011-05-31,2011-08-15,0.0,DEATH
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.13347022587269,2011-11-28,2012-08-31,0.0,DEATH
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.13347022587269,2011-11-28,2012-08-31,0.0,DEATH
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,9.13347022587269,2011-11-28,2012-08-31,0.0,DEATH
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.2197125256673513,2010-12-24,2011-03-31,0.0,DEATH
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.2197125256673513,2010-12-24,2011-03-31,0.0,DEATH
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.2197125256673513,2010-12-24,2011-03-31,0.0,DEATH
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.833675564681725,2011-06-23,2012-01-16,0.0,DEATH
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.833675564681725,2011-06-23,2012-01-16,0.0,DEATH
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.833675564681725,2011-06-23,2012-01-16,0.0,DEATH
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.891170431211499,2011-09-01,2011-11-27,0.0,DEATH
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.891170431211499,2011-09-01,2011-11-27,0.0,DEATH
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.891170431211499,2011-09-01,2011-11-27,0.0,DEATH
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.3182751540041067,2011-09-06,2011-12-15,0.0,DEATH
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.3182751540041067,2011-09-06,2011-12-15,0.0,DEATH
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.3182751540041067,2011-09-06,2011-12-15,0.0,DEATH
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.618069815195072,2012-02-20,2012-08-08,0.0,DEATH
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.618069815195072,2012-02-20,2012-08-08,0.0,DEATH
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.618069815195072,2012-02-20,2012-08-08,0.0,DEATH
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,35,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.917864476386037,2012-02-28,2012-10-25,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,35,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.917864476386037,2012-02-28,2012-10-25,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,35,1.0,2.0,Time to Death (months),TIME2DTH,1.0,7.917864476386037,2012-02-28,2012-10-25,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.402464065708419,2012-03-06,2012-07-17,0.0,DEATH
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.402464065708419,2012-03-06,2012-07-17,0.0,DEATH
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.402464065708419,2012-03-06,2012-07-17,0.0,DEATH
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.767967145790554,2012-03-26,2012-10-17,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.767967145790554,2012-03-26,2012-10-17,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.767967145790554,2012-03-26,2012-10-17,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,98,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.1067761806981515,2010-10-27,2011-02-28,0.0,DEATH
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,98,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.1067761806981515,2010-10-27,2011-02-28,0.0,DEATH
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,98,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.1067761806981515,2010-10-27,2011-02-28,0.0,DEATH
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.242299794661191,2010-11-23,2011-05-31,0.0,DEATH
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.242299794661191,2010-11-23,2011-05-31,0.0,DEATH
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.242299794661191,2010-11-23,2011-05-31,0.0,DEATH
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.19917864476386,2010-11-26,2011-09-01,0.0,DEATH
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.19917864476386,2010-11-26,2011-09-01,0.0,DEATH
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,9.19917864476386,2010-11-26,2011-09-01,0.0,DEATH
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.451745379876797,2010-12-14,2011-12-27,0.0,DEATH
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.451745379876797,2010-12-14,2011-12-27,0.0,DEATH
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,12.451745379876797,2010-12-14,2011-12-27,0.0,DEATH
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.659137577002053,2010-12-14,2011-10-03,0.0,DEATH
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.659137577002053,2010-12-14,2011-10-03,0.0,DEATH
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,9.659137577002053,2010-12-14,2011-10-03,0.0,DEATH
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.6427104722792607,2010-12-22,2011-02-09,0.0,DEATH
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.6427104722792607,2010-12-22,2011-02-09,0.0,DEATH
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.6427104722792607,2010-12-22,2011-02-09,0.0,DEATH
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.5256673511293635,2011-01-05,2011-01-20,0.0,DEATH
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.5256673511293635,2011-01-05,2011-01-20,0.0,DEATH
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.5256673511293635,2011-01-05,2011-01-20,0.0,DEATH
CO-101-001,CO-101-001-067-009,01067009,067,47.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.0369609856262834,2011-02-21,2011-04-23,0.0,DEATH
CO-101-001,CO-101-001-067-009,01067009,067,47.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.0369609856262834,2011-02-21,2011-04-23,0.0,DEATH
CO-101-001,CO-101-001-067-009,01067009,067,47.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.0369609856262834,2011-02-21,2011-04-23,0.0,DEATH
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.8870636550308009,2011-04-15,2011-05-11,0.0,DEATH
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.8870636550308009,2011-04-15,2011-05-11,0.0,DEATH
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.8870636550308009,2011-04-15,2011-05-11,0.0,DEATH
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,18.20123203285421,2011-04-22,2012-10-26,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,18.20123203285421,2011-04-22,2012-10-26,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1,1.0,2.0,Time to Death (months),TIME2DTH,1.0,18.20123203285421,2011-04-22,2012-10-26,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.9568788501026693,2011-04-28,2011-07-26,0.0,DEATH
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.9568788501026693,2011-04-28,2011-07-26,0.0,DEATH
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.9568788501026693,2011-04-28,2011-07-26,0.0,DEATH
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,15.178644763860369,2011-05-11,2012-08-14,0.0,DEATH
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,15.178644763860369,2011-05-11,2012-08-14,0.0,DEATH
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months),TIME2DTH,1.0,15.178644763860369,2011-05-11,2012-08-14,0.0,DEATH
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.6570841889117043,2011-05-11,2011-05-30,0.0,DEATH
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.6570841889117043,2011-05-11,2011-05-30,0.0,DEATH
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.6570841889117043,2011-05-11,2011-05-30,0.0,DEATH
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.172484599589322,2011-06-14,2011-10-18,0.0,DEATH
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.172484599589322,2011-06-14,2011-10-18,0.0,DEATH
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.172484599589322,2011-06-14,2011-10-18,0.0,DEATH
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.505133470225872,2011-06-20,2012-01-03,0.0,DEATH
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.505133470225872,2011-06-20,2012-01-03,0.0,DEATH
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.505133470225872,2011-06-20,2012-01-03,0.0,DEATH
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.3182751540041067,2011-08-02,2011-11-10,0.0,DEATH
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.3182751540041067,2011-08-02,2011-11-10,0.0,DEATH
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.3182751540041067,2011-08-02,2011-11-10,0.0,DEATH
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.574948665297741,2011-08-29,2012-05-15,0.0,DEATH
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.574948665297741,2011-08-29,2012-05-15,0.0,DEATH
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.574948665297741,2011-08-29,2012-05-15,0.0,DEATH
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,13.930184804928132,2011-08-31,2012-10-27,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,13.930184804928132,2011-08-31,2012-10-27,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,13.930184804928132,2011-08-31,2012-10-27,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.476386036960985,2011-09-21,2012-06-04,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.476386036960985,2011-09-21,2012-06-04,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.476386036960985,2011-09-21,2012-06-04,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.316221765913758,2011-12-15,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.316221765913758,2011-12-15,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,10.316221765913758,2011-12-15,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.29568788501026694,2011-12-26,2012-01-03,0.0,DEATH
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.29568788501026694,2011-12-26,2012-01-03,0.0,DEATH
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.29568788501026694,2011-12-26,2012-01-03,0.0,DEATH
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.330595482546201,2012-01-16,2012-10-25,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.330595482546201,2012-01-16,2012-10-25,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months),TIME2DTH,1.0,9.330595482546201,2012-01-16,2012-10-25,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.8542094455852156,2012-01-30,2012-02-24,0.0,DEATH
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.8542094455852156,2012-01-30,2012-02-24,0.0,DEATH
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.8542094455852156,2012-01-30,2012-02-24,0.0,DEATH
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.9425051334702257,2011-01-14,2011-05-13,0.0,DEATH
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.9425051334702257,2011-01-14,2011-05-13,0.0,DEATH
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.9425051334702257,2011-01-14,2011-05-13,0.0,DEATH
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,14.127310061601642,2011-01-14,2012-03-18,0.0,DEATH
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,14.127310061601642,2011-01-14,2012-03-18,0.0,DEATH
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months),TIME2DTH,1.0,14.127310061601642,2011-01-14,2012-03-18,0.0,DEATH
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.997946611909651,2011-02-15,2011-09-15,0.0,DEATH
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.997946611909651,2011-02-15,2011-09-15,0.0,DEATH
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.997946611909651,2011-02-15,2011-09-15,0.0,DEATH
CO-101-001,CO-101-001-069-002,01069002,069,46.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.242299794661191,2011-03-01,2011-09-06,0.0,DEATH
CO-101-001,CO-101-001-069-002,01069002,069,46.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.242299794661191,2011-03-01,2011-09-06,0.0,DEATH
CO-101-001,CO-101-001-069-002,01069002,069,46.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.242299794661191,2011-03-01,2011-09-06,0.0,DEATH
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.585215605749487,2011-04-26,2011-10-12,0.0,DEATH
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.585215605749487,2011-04-26,2011-10-12,0.0,DEATH
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.585215605749487,2011-04-26,2011-10-12,0.0,DEATH
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.646817248459959,2011-07-13,2011-10-31,0.0,DEATH
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.646817248459959,2011-07-13,2011-10-31,0.0,DEATH
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.646817248459959,2011-07-13,2011-10-31,0.0,DEATH
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.2813141683778233,2011-08-26,2011-10-03,0.0,DEATH
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.2813141683778233,2011-08-26,2011-10-03,0.0,DEATH
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.2813141683778233,2011-08-26,2011-10-03,0.0,DEATH
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.008213552361396,2011-02-09,2011-06-10,0.0,DEATH
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.008213552361396,2011-02-09,2011-06-10,0.0,DEATH
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,0.0,2.0,Time to Death (months),TIME2DTH,1.0,4.008213552361396,2011-02-09,2011-06-10,0.0,DEATH
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.9568788501026693,2011-02-07,2011-05-07,0.0,DEATH
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.9568788501026693,2011-02-07,2011-05-07,0.0,DEATH
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.9568788501026693,2011-02-07,2011-05-07,0.0,DEATH
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.067761806981519,2011-02-14,2011-11-16,0.0,DEATH
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.067761806981519,2011-02-14,2011-11-16,0.0,DEATH
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,0.0,2.0,Time to Death (months),TIME2DTH,1.0,9.067761806981519,2011-02-14,2011-11-16,0.0,DEATH
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.439425051334703,2011-02-15,2011-08-29,0.0,DEATH
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.439425051334703,2011-02-15,2011-08-29,0.0,DEATH
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.439425051334703,2011-02-15,2011-08-29,0.0,DEATH
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.6611909650924024,2011-03-24,2011-06-12,0.0,DEATH
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.6611909650924024,2011-03-24,2011-06-12,0.0,DEATH
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.6611909650924024,2011-03-24,2011-06-12,0.0,DEATH
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.8870636550308009,2011-04-21,2011-05-17,0.0,DEATH
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.8870636550308009,2011-04-21,2011-05-17,0.0,DEATH
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.8870636550308009,2011-04-21,2011-05-17,0.0,DEATH
CO-101-001,CO-101-001-070-014,01070014,070,32.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.104722792607802,2011-04-28,2012-03-30,0.0,DEATH
CO-101-001,CO-101-001-070-014,01070014,070,32.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.104722792607802,2011-04-28,2012-03-30,0.0,DEATH
CO-101-001,CO-101-001-070-014,01070014,070,32.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months),TIME2DTH,1.0,11.104722792607802,2011-04-28,2012-03-30,0.0,DEATH
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.6036960985626285,2011-04-29,2011-11-15,0.0,DEATH
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.6036960985626285,2011-04-29,2011-11-15,0.0,DEATH
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.6036960985626285,2011-04-29,2011-11-15,0.0,DEATH
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.583162217659138,2011-04-29,2012-05-15,0.0,DEATH
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.583162217659138,2011-04-29,2012-05-15,0.0,DEATH
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,12.583162217659138,2011-04-29,2012-05-15,0.0,DEATH
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.8726899383983573,2011-06-17,2011-08-12,0.0,DEATH
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.8726899383983573,2011-06-17,2011-08-12,0.0,DEATH
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.8726899383983573,2011-06-17,2011-08-12,0.0,DEATH
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.698151950718686,2011-06-20,2011-11-09,0.0,DEATH
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.698151950718686,2011-06-20,2011-11-09,0.0,DEATH
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.698151950718686,2011-06-20,2011-11-09,0.0,DEATH
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.476386036960985,2011-06-17,2012-02-29,0.0,DEATH
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.476386036960985,2011-06-17,2012-02-29,0.0,DEATH
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.476386036960985,2011-06-17,2012-02-29,0.0,DEATH
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.6036960985626285,2011-08-22,2012-03-09,0.0,DEATH
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.6036960985626285,2011-08-22,2012-03-09,0.0,DEATH
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.6036960985626285,2011-08-22,2012-03-09,0.0,DEATH
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.275154004106776,2011-08-24,2012-03-01,0.0,DEATH
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.275154004106776,2011-08-24,2012-03-01,0.0,DEATH
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.275154004106776,2011-08-24,2012-03-01,0.0,DEATH
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.034907597535934,2011-09-06,2012-06-06,0.0,DEATH
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.034907597535934,2011-09-06,2012-06-06,0.0,DEATH
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,1.0,2.0,Time to Death (months),TIME2DTH,1.0,9.034907597535934,2011-09-06,2012-06-06,0.0,DEATH
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.679671457905544,2011-09-20,2012-01-09,0.0,DEATH
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.679671457905544,2011-09-20,2012-01-09,0.0,DEATH
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.679671457905544,2011-09-20,2012-01-09,0.0,DEATH
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.501026694045175,2011-11-25,2012-04-09,0.0,DEATH
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.501026694045175,2011-11-25,2012-04-09,0.0,DEATH
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.501026694045175,2011-11-25,2012-04-09,0.0,DEATH
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.008213552361396,2011-12-06,2012-04-05,0.0,DEATH
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.008213552361396,2011-12-06,2012-04-05,0.0,DEATH
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,0.0,2.0,Time to Death (months),TIME2DTH,1.0,4.008213552361396,2011-12-06,2012-04-05,0.0,DEATH
CO-101-001,CO-101-001-070-033,01070033,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.724845995893224,2012-01-12,2012-11-02,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-070-033,01070033,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.724845995893224,2012-01-12,2012-11-02,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-070-033,01070033,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months),TIME2DTH,1.0,9.724845995893224,2012-01-12,2012-11-02,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.5338809034907595,2012-02-21,2012-07-07,0.0,DEATH
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.5338809034907595,2012-02-21,2012-07-07,0.0,DEATH
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.5338809034907595,2012-02-21,2012-07-07,0.0,DEATH
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.9281314168377826,2010-11-15,2011-04-13,0.0,DEATH
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.9281314168377826,2010-11-15,2011-04-13,0.0,DEATH
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.9281314168377826,2010-11-15,2011-04-13,0.0,DEATH
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,18.989733059548254,2010-11-17,2012-06-16,0.0,DEATH
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,18.989733059548254,2010-11-17,2012-06-16,0.0,DEATH
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,18.989733059548254,2010-11-17,2012-06-16,0.0,DEATH
CO-101-001,CO-101-001-071-003,01071003,071,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.049281314168377,2010-12-17,2011-08-18,0.0,DEATH
CO-101-001,CO-101-001-071-003,01071003,071,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.049281314168377,2010-12-17,2011-08-18,0.0,DEATH
CO-101-001,CO-101-001-071-003,01071003,071,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.049281314168377,2010-12-17,2011-08-18,0.0,DEATH
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,85,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.6611909650924024,2011-01-17,2011-04-07,0.0,DEATH
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,85,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.6611909650924024,2011-01-17,2011-04-07,0.0,DEATH
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,85,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.6611909650924024,2011-01-17,2011-04-07,0.0,DEATH
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.716632443531828,2011-01-25,2011-07-17,0.0,DEATH
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.716632443531828,2011-01-25,2011-07-17,0.0,DEATH
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.716632443531828,2011-01-25,2011-07-17,0.0,DEATH
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.336755646817249,2011-03-15,2011-07-24,0.0,DEATH
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.336755646817249,2011-03-15,2011-07-24,0.0,DEATH
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.336755646817249,2011-03-15,2011-07-24,0.0,DEATH
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.7351129363449695,2011-03-29,2011-10-19,0.0,DEATH
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.7351129363449695,2011-03-29,2011-10-19,0.0,DEATH
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.7351129363449695,2011-03-29,2011-10-19,0.0,DEATH
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.1971252566735113,2011-06-08,2011-06-13,0.0,DEATH
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.1971252566735113,2011-06-08,2011-06-13,0.0,DEATH
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.1971252566735113,2011-06-08,2011-06-13,0.0,DEATH
CO-101-001,CO-101-001-073-011,01073011,073,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.969199178644764,2012-01-25,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-073-011,01073011,073,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.969199178644764,2012-01-25,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-073-011,01073011,073,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.969199178644764,2012-01-25,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,65,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.1498973305954825,2012-02-22,2012-03-27,0.0,DEATH
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,65,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.1498973305954825,2012-02-22,2012-03-27,0.0,DEATH
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,65,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.1498973305954825,2012-02-22,2012-03-27,0.0,DEATH
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.008213552361396,2011-02-21,2011-06-22,0.0,DEATH
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.008213552361396,2011-02-21,2011-06-22,0.0,DEATH
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.008213552361396,2011-02-21,2011-06-22,0.0,DEATH
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.595482546201232,2011-08-25,2011-11-11,0.0,DEATH
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.595482546201232,2011-08-25,2011-11-11,0.0,DEATH
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.595482546201232,2011-08-25,2011-11-11,0.0,DEATH
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.4722792607802875,2011-09-21,2012-04-04,0.0,DEATH
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.4722792607802875,2011-09-21,2012-04-04,0.0,DEATH
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.4722792607802875,2011-09-21,2012-04-04,0.0,DEATH
CO-101-001,CO-101-001-075-005,01075005,075,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,45,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.303901437371663,2012-01-31,2012-06-09,0.0,DEATH
CO-101-001,CO-101-001-075-005,01075005,075,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,45,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.303901437371663,2012-01-31,2012-06-09,0.0,DEATH
CO-101-001,CO-101-001-075-005,01075005,075,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,45,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.303901437371663,2012-01-31,2012-06-09,0.0,DEATH
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.425051334702259,2012-03-07,2012-10-18,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.425051334702259,2012-03-07,2012-10-18,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2,0.0,2.0,Time to Death (months),TIME2DTH,1.0,7.425051334702259,2012-03-07,2012-10-18,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-076-001,01076001,076,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.1498973305954825,2011-06-22,2011-07-26,0.0,DEATH
CO-101-001,CO-101-001-076-001,01076001,076,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.1498973305954825,2011-06-22,2011-07-26,0.0,DEATH
CO-101-001,CO-101-001-076-001,01076001,076,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.1498973305954825,2011-06-22,2011-07-26,0.0,DEATH
CO-101-001,CO-101-001-076-002,01076002,076,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.8439425051334704,2012-02-28,2012-06-23,0.0,DEATH
CO-101-001,CO-101-001-076-002,01076002,076,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.8439425051334704,2012-02-28,2012-06-23,0.0,DEATH
CO-101-001,CO-101-001-076-002,01076002,076,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.8439425051334704,2012-02-28,2012-06-23,0.0,DEATH
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.158110882956879,2010-12-16,2011-05-21,0.0,DEATH
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.158110882956879,2010-12-16,2011-05-21,0.0,DEATH
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.158110882956879,2010-12-16,2011-05-21,0.0,DEATH
CO-101-001,CO-101-001-078-003,01078003,078,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.6940451745379876,2011-02-26,2011-05-18,0.0,DEATH
CO-101-001,CO-101-001-078-003,01078003,078,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.6940451745379876,2011-02-26,2011-05-18,0.0,DEATH
CO-101-001,CO-101-001-078-003,01078003,078,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.6940451745379876,2011-02-26,2011-05-18,0.0,DEATH
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.75564681724846,2011-05-11,2011-06-02,0.0,DEATH
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.75564681724846,2011-05-11,2011-06-02,0.0,DEATH
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.75564681724846,2011-05-11,2011-06-02,0.0,DEATH
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.176591375770021,2011-05-04,2011-11-07,0.0,DEATH
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.176591375770021,2011-05-04,2011-11-07,0.0,DEATH
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.176591375770021,2011-05-04,2011-11-07,0.0,DEATH
CO-101-001,CO-101-001-078-007,01078007,078,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.468172484599589,2011-05-18,2011-09-30,0.0,DEATH
CO-101-001,CO-101-001-078-007,01078007,078,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.468172484599589,2011-05-18,2011-09-30,0.0,DEATH
CO-101-001,CO-101-001-078-007,01078007,078,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.468172484599589,2011-05-18,2011-09-30,0.0,DEATH
CO-101-001,CO-101-001-078-009,01078009,078,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.936344969199178,2011-07-14,2012-04-10,0.0,DEATH
CO-101-001,CO-101-001-078-009,01078009,078,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.936344969199178,2011-07-14,2012-04-10,0.0,DEATH
CO-101-001,CO-101-001-078-009,01078009,078,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.936344969199178,2011-07-14,2012-04-10,0.0,DEATH
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.283367556468173,2011-11-28,2012-10-05,0.0,DEATH
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.283367556468173,2011-11-28,2012-10-05,0.0,DEATH
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,10.283367556468173,2011-11-28,2012-10-05,0.0,DEATH
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.679671457905544,2010-10-14,2011-02-02,0.0,DEATH
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.679671457905544,2010-10-14,2011-02-02,0.0,DEATH
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.679671457905544,2010-10-14,2011-02-02,0.0,DEATH
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.515400410677618,2010-10-21,2011-02-04,0.0,DEATH
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.515400410677618,2010-10-21,2011-02-04,0.0,DEATH
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.515400410677618,2010-10-21,2011-02-04,0.0,DEATH
CO-101-001,CO-101-001-079-006,01079006,079,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.509240246406572,2010-10-27,2011-07-12,0.0,DEATH
CO-101-001,CO-101-001-079-006,01079006,079,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.509240246406572,2010-10-27,2011-07-12,0.0,DEATH
CO-101-001,CO-101-001-079-006,01079006,079,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.509240246406572,2010-10-27,2011-07-12,0.0,DEATH
CO-101-001,CO-101-001-079-009,01079009,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,15.080082135523615,2010-10-27,2012-01-28,0.0,DEATH
CO-101-001,CO-101-001-079-009,01079009,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,15.080082135523615,2010-10-27,2012-01-28,0.0,DEATH
CO-101-001,CO-101-001-079-009,01079009,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months),TIME2DTH,1.0,15.080082135523615,2010-10-27,2012-01-28,0.0,DEATH
CO-101-001,CO-101-001-079-010,01079010,079,68.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.8542094455852156,2010-11-07,2010-12-02,0.0,DEATH
CO-101-001,CO-101-001-079-010,01079010,079,68.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.8542094455852156,2010-11-07,2010-12-02,0.0,DEATH
CO-101-001,CO-101-001-079-010,01079010,079,68.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.8542094455852156,2010-11-07,2010-12-02,0.0,DEATH
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.7207392197125255,2011-01-26,2011-09-17,0.0,DEATH
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.7207392197125255,2011-01-26,2011-09-17,0.0,DEATH
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,7.7207392197125255,2011-01-26,2011-09-17,0.0,DEATH
CO-101-001,CO-101-001-079-013,01079013,079,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.367556468172484,2011-02-22,2012-02-02,0.0,DEATH
CO-101-001,CO-101-001-079-013,01079013,079,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.367556468172484,2011-02-22,2012-02-02,0.0,DEATH
CO-101-001,CO-101-001-079-013,01079013,079,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2,1.0,2.0,Time to Death (months),TIME2DTH,1.0,11.367556468172484,2011-02-22,2012-02-02,0.0,DEATH
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,45,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.04517453798768,2011-04-14,2011-10-14,0.0,DEATH
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,45,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.04517453798768,2011-04-14,2011-10-14,0.0,DEATH
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,45,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.04517453798768,2011-04-14,2011-10-14,0.0,DEATH
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,13.273100616016427,2011-05-19,2012-06-25,0.0,DEATH
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,13.273100616016427,2011-05-19,2012-06-25,0.0,DEATH
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,13.273100616016427,2011-05-19,2012-06-25,0.0,DEATH
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,15.211498973305956,2011-07-28,2012-11-01,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,15.211498973305956,2011-07-28,2012-11-01,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months),TIME2DTH,1.0,15.211498973305956,2011-07-28,2012-11-01,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.104722792607802,2011-07-21,2012-06-22,0.0,DEATH
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.104722792607802,2011-07-21,2012-06-22,0.0,DEATH
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months),TIME2DTH,1.0,11.104722792607802,2011-07-21,2012-06-22,0.0,DEATH
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.5585215605749486,2011-10-10,2011-10-26,0.0,DEATH
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.5585215605749486,2011-10-10,2011-10-26,0.0,DEATH
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.5585215605749486,2011-10-10,2011-10-26,0.0,DEATH
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.628336755646817,2011-11-01,2012-01-19,0.0,DEATH
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.628336755646817,2011-11-01,2012-01-19,0.0,DEATH
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.628336755646817,2011-11-01,2012-01-19,0.0,DEATH
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.7453798767967146,2011-10-31,2012-02-21,0.0,DEATH
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.7453798767967146,2011-10-31,2012-02-21,0.0,DEATH
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.7453798767967146,2011-10-31,2012-02-21,0.0,DEATH
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.02464065708419,2011-11-01,2012-10-31,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.02464065708419,2011-11-01,2012-10-31,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months),TIME2DTH,1.0,12.02464065708419,2011-11-01,2012-10-31,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.687885010266941,2011-11-16,2012-07-06,0.0,DEATH
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.687885010266941,2011-11-16,2012-07-06,0.0,DEATH
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,7.687885010266941,2011-11-16,2012-07-06,0.0,DEATH
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.2484599589322383,2011-11-28,2012-01-04,0.0,DEATH
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.2484599589322383,2011-11-28,2012-01-04,0.0,DEATH
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.2484599589322383,2011-11-28,2012-01-04,0.0,DEATH
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,85,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.4271047227926078,2011-12-12,2011-12-24,0.0,DEATH
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,85,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.4271047227926078,2011-12-12,2011-12-24,0.0,DEATH
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,85,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.4271047227926078,2011-12-12,2011-12-24,0.0,DEATH
CO-101-001,CO-101-001-079-027,01079027,079,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.151950718685832,2011-12-26,2012-10-29,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-079-027,01079027,079,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.151950718685832,2011-12-26,2012-10-29,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-079-027,01079027,079,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,2.0,Time to Death (months),TIME2DTH,1.0,10.151950718685832,2011-12-26,2012-10-29,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.420944558521561,2012-01-10,2012-06-22,0.0,DEATH
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.420944558521561,2012-01-10,2012-06-22,0.0,DEATH
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.420944558521561,2012-01-10,2012-06-22,0.0,DEATH
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.4784394250513346,2012-01-26,2012-03-10,0.0,DEATH
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.4784394250513346,2012-01-26,2012-03-10,0.0,DEATH
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.4784394250513346,2012-01-26,2012-03-10,0.0,DEATH
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,19.318275154004105,2010-10-07,2012-05-16,0.0,DEATH
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,19.318275154004105,2010-10-07,2012-05-16,0.0,DEATH
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,19.318275154004105,2010-10-07,2012-05-16,0.0,DEATH
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.344969199178644,2010-10-27,2011-07-07,0.0,DEATH
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.344969199178644,2010-10-27,2011-07-07,0.0,DEATH
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.344969199178644,2010-10-27,2011-07-07,0.0,DEATH
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.02464065708419,2011-01-25,2012-01-25,0.0,DEATH
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.02464065708419,2011-01-25,2012-01-25,0.0,DEATH
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,12.02464065708419,2011-01-25,2012-01-25,0.0,DEATH
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,19.581108829568787,2011-02-08,2012-09-25,0.0,DEATH
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,19.581108829568787,2011-02-08,2012-09-25,0.0,DEATH
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months),TIME2DTH,1.0,19.581108829568787,2011-02-08,2012-09-25,0.0,DEATH
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.965092402464066,2011-02-25,2011-09-24,0.0,DEATH
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.965092402464066,2011-02-25,2011-09-24,0.0,DEATH
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.965092402464066,2011-02-25,2011-09-24,0.0,DEATH
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.476386036960985,2011-04-27,2012-01-09,0.0,DEATH
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.476386036960985,2011-04-27,2012-01-09,0.0,DEATH
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,80,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.476386036960985,2011-04-27,2012-01-09,0.0,DEATH
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,17.248459958932237,2011-05-18,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,17.248459958932237,2011-05-18,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,17.248459958932237,2011-05-18,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.9568788501026693,2011-05-25,2011-08-22,0.0,DEATH
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.9568788501026693,2011-05-25,2011-08-22,0.0,DEATH
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.9568788501026693,2011-05-25,2011-08-22,0.0,DEATH
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.8439425051334704,2011-06-01,2011-09-25,0.0,DEATH
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.8439425051334704,2011-06-01,2011-09-25,0.0,DEATH
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.8439425051334704,2011-06-01,2011-09-25,0.0,DEATH
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.5482546201232035,2011-07-18,2011-11-02,0.0,DEATH
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.5482546201232035,2011-07-18,2011-11-02,0.0,DEATH
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.5482546201232035,2011-07-18,2011-11-02,0.0,DEATH
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.008213552361396,2011-09-09,2012-01-08,0.0,DEATH
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.008213552361396,2011-09-09,2012-01-08,0.0,DEATH
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.008213552361396,2011-09-09,2012-01-08,0.0,DEATH
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.626283367556468,2011-09-09,2012-06-27,0.0,DEATH
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.626283367556468,2011-09-09,2012-06-27,0.0,DEATH
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,9.626283367556468,2011-09-09,2012-06-27,0.0,DEATH
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.786447638603696,2011-09-14,2012-05-07,0.0,DEATH
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.786447638603696,2011-09-14,2012-05-07,0.0,DEATH
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,7.786447638603696,2011-09-14,2012-05-07,0.0,DEATH
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.186858316221766,2011-09-14,2011-12-19,0.0,DEATH
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.186858316221766,2011-09-14,2011-12-19,0.0,DEATH
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.186858316221766,2011-09-14,2011-12-19,0.0,DEATH
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.004106776180698,2011-09-16,2011-11-15,0.0,DEATH
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.004106776180698,2011-09-16,2011-11-15,0.0,DEATH
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.004106776180698,2011-09-16,2011-11-15,0.0,DEATH
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.344969199178644,2011-09-28,2012-06-07,0.0,DEATH
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.344969199178644,2011-09-28,2012-06-07,0.0,DEATH
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,90,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.344969199178644,2011-09-28,2012-06-07,0.0,DEATH
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.848049281314168,2011-10-05,2012-03-30,0.0,DEATH
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.848049281314168,2011-10-05,2012-03-30,0.0,DEATH
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.848049281314168,2011-10-05,2012-03-30,0.0,DEATH
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.2197125256673513,2011-10-12,2012-01-17,0.0,DEATH
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.2197125256673513,2011-10-12,2012-01-17,0.0,DEATH
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.2197125256673513,2011-10-12,2012-01-17,0.0,DEATH
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.698151950718686,2011-11-17,2012-04-07,0.0,DEATH
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.698151950718686,2011-11-17,2012-04-07,0.0,DEATH
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.698151950718686,2011-11-17,2012-04-07,0.0,DEATH
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.9055441478439425,2011-11-21,2012-01-17,0.0,DEATH
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.9055441478439425,2011-11-21,2012-01-17,0.0,DEATH
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.9055441478439425,2011-11-21,2012-01-17,0.0,DEATH
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.739219712525667,2011-11-30,2012-08-21,0.0,DEATH
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.739219712525667,2011-11-30,2012-08-21,0.0,DEATH
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.739219712525667,2011-11-30,2012-08-21,0.0,DEATH
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.1971252566735113,2012-01-05,2012-01-10,0.0,DEATH
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.1971252566735113,2012-01-05,2012-01-10,0.0,DEATH
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.1971252566735113,2012-01-05,2012-01-10,0.0,DEATH
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.628336755646817,2011-12-29,2012-03-17,0.0,DEATH
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.628336755646817,2011-12-29,2012-03-17,0.0,DEATH
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,100,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.628336755646817,2011-12-29,2012-03-17,0.0,DEATH
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.468172484599589,2012-01-23,2012-06-06,0.0,DEATH
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.468172484599589,2012-01-23,2012-06-06,0.0,DEATH
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.468172484599589,2012-01-23,2012-06-06,0.0,DEATH
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.04517453798768,2012-02-29,2012-08-30,0.0,DEATH
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.04517453798768,2012-02-29,2012-08-30,0.0,DEATH
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.04517453798768,2012-02-29,2012-08-30,0.0,DEATH
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.026694045174538,2012-03-07,2012-08-06,0.0,DEATH
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.026694045174538,2012-03-07,2012-08-06,0.0,DEATH
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.026694045174538,2012-03-07,2012-08-06,0.0,DEATH
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.7782340862423,2012-04-03,2012-07-26,0.0,DEATH
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.7782340862423,2012-04-03,2012-07-26,0.0,DEATH
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.7782340862423,2012-04-03,2012-07-26,0.0,DEATH
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,75,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.406570841889117,2012-04-03,2012-10-14,0.0,DEATH
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,75,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.406570841889117,2012-04-03,2012-10-14,0.0,DEATH
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,75,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.406570841889117,2012-04-03,2012-10-14,0.0,DEATH
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.815195071868583,2010-11-09,2011-05-04,0.0,DEATH
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.815195071868583,2010-11-09,2011-05-04,0.0,DEATH
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.815195071868583,2010-11-09,2011-05-04,0.0,DEATH
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.663244353182751,2010-12-10,2011-11-29,0.0,DEATH
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.663244353182751,2010-12-10,2011-11-29,0.0,DEATH
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,70,1.0,2.0,Time to Death (months),TIME2DTH,1.0,11.663244353182751,2010-12-10,2011-11-29,0.0,DEATH
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.64476386036961,2011-02-07,2011-12-27,0.0,DEATH
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.64476386036961,2011-02-07,2011-12-27,0.0,DEATH
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months),TIME2DTH,1.0,10.64476386036961,2011-02-07,2011-12-27,0.0,DEATH
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.379876796714579,2011-03-03,2011-04-13,0.0,DEATH
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.379876796714579,2011-03-03,2011-04-13,0.0,DEATH
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.379876796714579,2011-03-03,2011-04-13,0.0,DEATH
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.646817248459959,2011-08-01,2011-11-19,0.0,DEATH
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.646817248459959,2011-08-01,2011-11-19,0.0,DEATH
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.646817248459959,2011-08-01,2011-11-19,0.0,DEATH
CO-101-001,CO-101-001-081-011,01081011,081,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.8254620123203287,2011-11-25,2012-02-18,0.0,DEATH
CO-101-001,CO-101-001-081-011,01081011,081,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.8254620123203287,2011-11-25,2012-02-18,0.0,DEATH
CO-101-001,CO-101-001-081-011,01081011,081,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.8254620123203287,2011-11-25,2012-02-18,0.0,DEATH
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.626283367556468,2012-01-04,2012-10-22,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.626283367556468,2012-01-04,2012-10-22,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months),TIME2DTH,1.0,9.626283367556468,2012-01-04,2012-10-22,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.505133470225872,2010-10-30,2011-05-15,0.0,DEATH
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.505133470225872,2010-10-30,2011-05-15,0.0,DEATH
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.505133470225872,2010-10-30,2011-05-15,0.0,DEATH
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.3470225872689938,2011-02-04,2011-03-16,0.0,DEATH
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.3470225872689938,2011-02-04,2011-03-16,0.0,DEATH
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.3470225872689938,2011-02-04,2011-03-16,0.0,DEATH
CO-101-001,CO-101-001-082-004,01082004,082,69.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,13.568788501026694,2011-03-11,2012-04-26,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-082-004,01082004,082,69.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,13.568788501026694,2011-03-11,2012-04-26,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-082-004,01082004,082,69.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,2.0,Time to Death (months),TIME2DTH,1.0,13.568788501026694,2011-03-11,2012-04-26,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.186858316221766,2011-03-09,2011-06-13,0.0,DEATH
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.186858316221766,2011-03-09,2011-06-13,0.0,DEATH
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.186858316221766,2011-03-09,2011-06-13,0.0,DEATH
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.0369609856262834,2011-04-13,2011-06-13,0.0,DEATH
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.0369609856262834,2011-04-13,2011-06-13,0.0,DEATH
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.0369609856262834,2011-04-13,2011-06-13,0.0,DEATH
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.80082135523614,2011-08-10,2012-03-03,0.0,DEATH
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.80082135523614,2011-08-10,2012-03-03,0.0,DEATH
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.80082135523614,2011-08-10,2012-03-03,0.0,DEATH
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.1683778234086244,2011-09-20,2011-11-24,0.0,DEATH
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.1683778234086244,2011-09-20,2011-11-24,0.0,DEATH
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.1683778234086244,2011-09-20,2011-11-24,0.0,DEATH
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.501026694045175,2011-11-21,2012-04-05,0.0,DEATH
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.501026694045175,2011-11-21,2012-04-05,0.0,DEATH
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.501026694045175,2011-11-21,2012-04-05,0.0,DEATH
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.252566735112936,2011-11-28,2012-03-05,0.0,DEATH
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.252566735112936,2011-11-28,2012-03-05,0.0,DEATH
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months),TIME2DTH,1.0,3.252566735112936,2011-11-28,2012-03-05,0.0,DEATH
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.2669404517453797,2011-11-28,2012-02-04,0.0,DEATH
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.2669404517453797,2011-11-28,2012-02-04,0.0,DEATH
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.2669404517453797,2011-11-28,2012-02-04,0.0,DEATH
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.414784394250514,2011-12-12,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.414784394250514,2011-12-12,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,10.414784394250514,2011-12-12,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.919917864476386,2012-01-25,2012-02-21,0.0,DEATH
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.919917864476386,2012-01-25,2012-02-21,0.0,DEATH
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,0.919917864476386,2012-01-25,2012-02-21,0.0,DEATH
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.917864476386037,2012-02-27,2012-10-24,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.917864476386037,2012-02-27,2012-10-24,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,7.917864476386037,2012-02-27,2012-10-24,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,85,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.158110882956879,2012-02-27,2012-08-01,0.0,DEATH
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,85,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.158110882956879,2012-02-27,2012-08-01,0.0,DEATH
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,85,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.158110882956879,2012-02-27,2012-08-01,0.0,DEATH
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,14.225872689938399,2011-04-06,2012-06-11,0.0,DEATH
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,14.225872689938399,2011-04-06,2012-06-11,0.0,DEATH
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months),TIME2DTH,1.0,14.225872689938399,2011-04-06,2012-06-11,0.0,DEATH
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.924024640657084,2011-05-18,2011-08-14,0.0,DEATH
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.924024640657084,2011-05-18,2011-08-14,0.0,DEATH
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,2.924024640657084,2011-05-18,2011-08-14,0.0,DEATH
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.8069815195071868,2011-07-12,2011-09-04,0.0,DEATH
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.8069815195071868,2011-07-12,2011-09-04,0.0,DEATH
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.8069815195071868,2011-07-12,2011-09-04,0.0,DEATH
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.618069815195072,2011-10-04,2012-03-22,0.0,DEATH
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.618069815195072,2011-10-04,2012-03-22,0.0,DEATH
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.618069815195072,2011-10-04,2012-03-22,0.0,DEATH
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.184804928131417,2011-12-19,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.184804928131417,2011-12-19,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,2.0,Time to Death (months),TIME2DTH,1.0,10.184804928131417,2011-12-19,2012-10-23,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.205338809034908,2011-12-19,2012-04-24,0.0,DEATH
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.205338809034908,2011-12-19,2012-04-24,0.0,DEATH
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.205338809034908,2011-12-19,2012-04-24,0.0,DEATH
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,N/A,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.650924024640657,2011-12-26,2012-06-14,0.0,DEATH
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,N/A,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.650924024640657,2011-12-26,2012-06-14,0.0,DEATH
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,N/A,1.0,2.0,Time to Death (months),TIME2DTH,1.0,5.650924024640657,2011-12-26,2012-06-14,0.0,DEATH
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.837782340862423,2012-01-23,2012-10-17,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.837782340862423,2012-01-23,2012-10-17,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,8.837782340862423,2012-01-23,2012-10-17,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-084-012,01084012,084,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.5441478439425051,2012-03-05,2012-04-20,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-084-012,01084012,084,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.5441478439425051,2012-03-05,2012-04-20,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-084-012,01084012,084,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,2.0,Time to Death (months),TIME2DTH,1.0,1.5441478439425051,2012-03-05,2012-04-20,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.073921971252567,2011-04-14,2011-08-15,0.0,DEATH
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.073921971252567,2011-04-14,2011-08-15,0.0,DEATH
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,4.073921971252567,2011-04-14,2011-08-15,0.0,DEATH
CO-101-001,CO-101-001-085-002,01085002,085,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,14.850102669404517,2011-05-10,2012-08-03,0.0,DEATH
CO-101-001,CO-101-001-085-002,01085002,085,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,14.850102669404517,2011-05-10,2012-08-03,0.0,DEATH
CO-101-001,CO-101-001-085-002,01085002,085,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,2.0,Time to Death (months),TIME2DTH,1.0,14.850102669404517,2011-05-10,2012-08-03,0.0,DEATH
CO-101-001,CO-101-001-086-003,01086003,086,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.055441478439425,2010-11-25,2011-02-25,0.0,DEATH
CO-101-001,CO-101-001-086-003,01086003,086,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.055441478439425,2010-11-25,2011-02-25,0.0,DEATH
CO-101-001,CO-101-001-086-003,01086003,086,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15,0.0,2.0,Time to Death (months),TIME2DTH,1.0,3.055441478439425,2010-11-25,2011-02-25,0.0,DEATH
CO-101-001,CO-101-001-086-004,01086004,086,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.3613963039014374,2011-03-17,2011-03-27,0.0,DEATH
CO-101-001,CO-101-001-086-004,01086004,086,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.3613963039014374,2011-03-17,2011-03-27,0.0,DEATH
CO-101-001,CO-101-001-086-004,01086004,086,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,2.0,Time to Death (months),TIME2DTH,1.0,0.3613963039014374,2011-03-17,2011-03-27,0.0,DEATH
CO-101-001,CO-101-001-086-005,01086005,086,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.880903490759754,2011-04-11,2011-10-06,0.0,DEATH
CO-101-001,CO-101-001-086-005,01086005,086,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.880903490759754,2011-04-11,2011-10-06,0.0,DEATH
CO-101-001,CO-101-001-086-005,01086005,086,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,2.0,Time to Death (months),TIME2DTH,1.0,5.880903490759754,2011-04-11,2011-10-06,0.0,DEATH
CO-101-001,CO-101-001-086-006,01086006,086,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.4127310061601643,2011-04-19,2011-05-31,0.0,DEATH
CO-101-001,CO-101-001-086-006,01086006,086,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.4127310061601643,2011-04-19,2011-05-31,0.0,DEATH
CO-101-001,CO-101-001-086-006,01086006,086,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,0.0,2.0,Time to Death (months),TIME2DTH,1.0,1.4127310061601643,2011-04-19,2011-05-31,0.0,DEATH
CO-101-001,CO-101-001-086-007,01086007,086,74.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.242299794661191,2011-05-31,2011-12-06,0.0,DEATH
CO-101-001,CO-101-001-086-007,01086007,086,74.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.242299794661191,2011-05-31,2011-12-06,0.0,DEATH
CO-101-001,CO-101-001-086-007,01086007,086,74.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,2.0,Time to Death (months),TIME2DTH,1.0,6.242299794661191,2011-05-31,2011-12-06,0.0,DEATH
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,0.0,2.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.993839835728953,2011-07-12,2011-12-10,0.0,DEATH
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,0.0,2.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.993839835728953,2011-07-12,2011-12-10,0.0,DEATH
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Eastern Europe,3.0,Eastern Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,0.0,2.0,Time to Death (months),TIME2DTH,1.0,4.993839835728953,2011-07-12,2011-12-10,0.0,DEATH
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.114989733059549,2011-06-08,2012-02-09,0.0,DEATH
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.114989733059549,2011-06-08,2012-02-09,0.0,DEATH
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months),TIME2DTH,1.0,8.114989733059549,2011-06-08,2012-02-09,0.0,DEATH
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.618069815195072,2011-05-30,2011-11-16,0.0,DEATH
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.618069815195072,2011-05-30,2011-11-16,0.0,DEATH
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.618069815195072,2011-05-30,2011-11-16,0.0,DEATH
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.8870636550308009,2011-06-09,2011-07-05,0.0,DEATH
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.8870636550308009,2011-06-09,2011-07-05,0.0,DEATH
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.8870636550308009,2011-06-09,2011-07-05,0.0,DEATH
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,45,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.082135523613964,2011-07-11,2012-03-12,0.0,DEATH
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,45,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.082135523613964,2011-07-11,2012-03-12,0.0,DEATH
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,45,0.0,1.0,Time to Death (months),TIME2DTH,1.0,8.082135523613964,2011-07-11,2012-03-12,0.0,DEATH
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.813141683778234,2011-07-12,2012-08-04,0.0,DEATH
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.813141683778234,2011-07-12,2012-08-04,0.0,DEATH
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,12.813141683778234,2011-07-12,2012-08-04,0.0,DEATH
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,15.014373716632443,2011-07-12,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,15.014373716632443,2011-07-12,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months),TIME2DTH,1.0,15.014373716632443,2011-07-12,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.595482546201232,2011-09-15,2011-12-02,0.0,DEATH
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.595482546201232,2011-09-15,2011-12-02,0.0,DEATH
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.595482546201232,2011-09-15,2011-12-02,0.0,DEATH
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.104722792607802,2011-11-09,2012-10-11,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.104722792607802,2011-11-09,2012-10-11,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months),TIME2DTH,1.0,11.104722792607802,2011-11-09,2012-10-11,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.95482546201232,2011-12-20,2012-10-17,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.95482546201232,2011-12-20,2012-10-17,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15,0.0,1.0,Time to Death (months),TIME2DTH,1.0,9.95482546201232,2011-12-20,2012-10-17,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.739219712525667,2012-01-11,2012-10-02,0.0,DEATH
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.739219712525667,2012-01-11,2012-10-02,0.0,DEATH
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.739219712525667,2012-01-11,2012-10-02,0.0,DEATH
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.283367556468173,2011-01-19,2011-11-27,0.0,DEATH
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.283367556468173,2011-01-19,2011-11-27,0.0,DEATH
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40,0.0,1.0,Time to Death (months),TIME2DTH,1.0,10.283367556468173,2011-01-19,2011-11-27,0.0,DEATH
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.223819301848049,2011-06-21,2011-11-26,0.0,DEATH
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.223819301848049,2011-06-21,2011-11-26,0.0,DEATH
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.223819301848049,2011-06-21,2011-11-26,0.0,DEATH
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,15.178644763860369,2011-06-29,2012-10-02,0.0,DEATH
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,15.178644763860369,2011-06-29,2012-10-02,0.0,DEATH
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,0.0,1.0,Time to Death (months),TIME2DTH,1.0,15.178644763860369,2011-06-29,2012-10-02,0.0,DEATH
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.055441478439425,2012-01-18,2012-04-19,0.0,DEATH
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.055441478439425,2012-01-18,2012-04-19,0.0,DEATH
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.055441478439425,2012-01-18,2012-04-19,0.0,DEATH
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.944558521560575,2010-12-13,2012-01-10,0.0,DEATH
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.944558521560575,2010-12-13,2012-01-10,0.0,DEATH
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30,0.0,1.0,Time to Death (months),TIME2DTH,1.0,12.944558521560575,2010-12-13,2012-01-10,0.0,DEATH
CO-101-001,CO-101-001-090-002,01090002,090,63.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,13.503080082135524,2011-03-15,2012-04-28,0.0,DEATH
CO-101-001,CO-101-001-090-002,01090002,090,63.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,13.503080082135524,2011-03-15,2012-04-28,0.0,DEATH
CO-101-001,CO-101-001-090-002,01090002,090,63.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months),TIME2DTH,1.0,13.503080082135524,2011-03-15,2012-04-28,0.0,DEATH
CO-101-001,CO-101-001-090-003,01090003,090,55.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.650924024640657,2011-04-08,2011-09-26,0.0,DEATH
CO-101-001,CO-101-001-090-003,01090003,090,55.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.650924024640657,2011-04-08,2011-09-26,0.0,DEATH
CO-101-001,CO-101-001-090-003,01090003,090,55.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months),TIME2DTH,1.0,5.650924024640657,2011-04-08,2011-09-26,0.0,DEATH
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.761806981519507,2011-05-30,2012-05-21,0.0,DEATH
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.761806981519507,2011-05-30,2012-05-21,0.0,DEATH
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months),TIME2DTH,1.0,11.761806981519507,2011-05-30,2012-05-21,0.0,DEATH
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.731006160164271,2011-05-30,2011-10-20,0.0,DEATH
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.731006160164271,2011-05-30,2011-10-20,0.0,DEATH
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Western Europe,2.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,0.0,1.0,Time to Death (months),TIME2DTH,1.0,4.731006160164271,2011-05-30,2011-10-20,0.0,DEATH
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,23.62217659137577,2010-11-12,2012-10-30,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,23.62217659137577,2010-11-12,2012-10-30,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,0.0,1.0,Time to Death (months),TIME2DTH,1.0,23.62217659137577,2010-11-12,2012-10-30,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.527720739219713,2011-08-05,2012-05-20,0.0,DEATH
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.527720739219713,2011-08-05,2012-05-20,0.0,DEATH
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months),TIME2DTH,1.0,9.527720739219713,2011-08-05,2012-05-20,0.0,DEATH
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.431211498973306,2012-02-08,2012-04-21,0.0,DEATH
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.431211498973306,2012-02-08,2012-04-21,0.0,DEATH
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.431211498973306,2012-02-08,2012-04-21,0.0,DEATH
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.308008213552362,2012-02-17,2012-08-26,0.0,DEATH
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.308008213552362,2012-02-17,2012-08-26,0.0,DEATH
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,6.308008213552362,2012-02-17,2012-08-26,0.0,DEATH
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.059548254620124,2012-03-19,2012-08-19,0.0,DEATH
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.059548254620124,2012-03-19,2012-08-19,0.0,DEATH
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.059548254620124,2012-03-19,2012-08-19,0.0,DEATH
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.960985626283367,2011-06-24,2011-11-21,0.0,DEATH
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.960985626283367,2011-06-24,2011-11-21,0.0,DEATH
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.960985626283367,2011-06-24,2011-11-21,0.0,DEATH
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.607802874743326,2011-08-05,2012-04-22,0.0,DEATH
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.607802874743326,2011-08-05,2012-04-22,0.0,DEATH
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.607802874743326,2011-08-05,2012-04-22,0.0,DEATH
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.0184804928131417,2011-10-11,2011-11-10,0.0,DEATH
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.0184804928131417,2011-10-11,2011-11-10,0.0,DEATH
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.0184804928131417,2011-10-11,2011-11-10,0.0,DEATH
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.731006160164271,2012-01-04,2012-05-26,0.0,DEATH
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.731006160164271,2012-01-04,2012-05-26,0.0,DEATH
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.731006160164271,2012-01-04,2012-05-26,0.0,DEATH
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.75564681724846,2012-02-07,2012-02-29,0.0,DEATH
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.75564681724846,2012-02-07,2012-02-29,0.0,DEATH
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.75564681724846,2012-02-07,2012-02-29,0.0,DEATH
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,12.386036960985626,2011-08-24,2012-09-03,0.0,DEATH
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,12.386036960985626,2011-08-24,2012-09-03,0.0,DEATH
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months),TIME2DTH,1.0,12.386036960985626,2011-08-24,2012-09-03,0.0,DEATH
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.8069815195071868,2011-08-15,2011-10-08,0.0,DEATH
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.8069815195071868,2011-08-15,2011-10-08,0.0,DEATH
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.8069815195071868,2011-08-15,2011-10-08,0.0,DEATH
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.190965092402464,2012-02-07,2012-07-13,0.0,DEATH
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.190965092402464,2012-02-07,2012-07-13,0.0,DEATH
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.190965092402464,2012-02-07,2012-07-13,0.0,DEATH
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.4435318275154,2012-02-17,2012-10-30,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.4435318275154,2012-02-17,2012-10-30,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.4435318275154,2012-02-17,2012-10-30,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,95,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.9383983572895278,2012-04-09,2012-06-06,0.0,DEATH
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,95,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.9383983572895278,2012-04-09,2012-06-06,0.0,DEATH
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,95,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.9383983572895278,2012-04-09,2012-06-06,0.0,DEATH
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.125256673511293,2011-12-12,2012-05-15,0.0,DEATH
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.125256673511293,2011-12-12,2012-05-15,0.0,DEATH
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.125256673511293,2011-12-12,2012-05-15,0.0,DEATH
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,10.349075975359343,2011-09-19,2012-07-29,0.0,DEATH
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,10.349075975359343,2011-09-19,2012-07-29,0.0,DEATH
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,0.0,1.0,Time to Death (months),TIME2DTH,1.0,10.349075975359343,2011-09-19,2012-07-29,0.0,DEATH
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,1.8726899383983573,2011-10-06,2011-12-01,0.0,DEATH
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,1.8726899383983573,2011-10-06,2011-12-01,0.0,DEATH
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,90,1.0,1.0,Time to Death (months),TIME2DTH,1.0,1.8726899383983573,2011-10-06,2011-12-01,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.759753593429158,2011-10-26,2012-01-17,0.0,DEATH
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.759753593429158,2011-10-26,2012-01-17,0.0,DEATH
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35,1.0,1.0,Time to Death (months),TIME2DTH,1.0,2.759753593429158,2011-10-26,2012-01-17,0.0,DEATH
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.965092402464066,2011-11-09,2012-06-07,0.0,DEATH
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.965092402464066,2011-11-09,2012-06-07,0.0,DEATH
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months),TIME2DTH,1.0,6.965092402464066,2011-11-09,2012-06-07,0.0,DEATH
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.082135523613964,2011-12-23,2012-08-24,0.0,DEATH
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.082135523613964,2011-12-23,2012-08-24,0.0,DEATH
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.082135523613964,2011-12-23,2012-08-24,0.0,DEATH
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.31211498973306,2012-02-14,2012-10-23,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.31211498973306,2012-02-14,2012-10-23,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.31211498973306,2012-02-14,2012-10-23,1.0,CENSORED AT TIME OF LAST VISIT
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,6.373716632443532,2012-03-23,2012-10-02,0.0,DEATH
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,6.373716632443532,2012-03-23,2012-10-02,0.0,DEATH
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25,1.0,1.0,Time to Death (months),TIME2DTH,1.0,6.373716632443532,2012-03-23,2012-10-02,0.0,DEATH
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,13.60164271047228,2011-06-20,2012-08-06,0.0,DEATH
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,13.60164271047228,2011-06-20,2012-08-06,0.0,DEATH
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30,1.0,1.0,Time to Death (months),TIME2DTH,1.0,13.60164271047228,2011-06-20,2012-08-06,0.0,DEATH
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,95,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.016427104722792,2011-06-29,2012-02-27,0.0,DEATH
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,95,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.016427104722792,2011-06-29,2012-02-27,0.0,DEATH
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,95,1.0,1.0,Time to Death (months),TIME2DTH,1.0,8.016427104722792,2011-06-29,2012-02-27,0.0,DEATH
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.9425051334702257,2011-07-19,2011-11-15,0.0,DEATH
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.9425051334702257,2011-07-19,2011-11-15,0.0,DEATH
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,1.0,1.0,Time to Death (months),TIME2DTH,1.0,3.9425051334702257,2011-07-19,2011-11-15,0.0,DEATH
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.749486652977413,2012-01-27,2012-07-19,0.0,DEATH
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.749486652977413,2012-01-27,2012-07-19,0.0,DEATH
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,95,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.749486652977413,2012-01-27,2012-07-19,0.0,DEATH
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.62217659137577,2011-08-03,2012-03-21,0.0,DEATH
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.62217659137577,2011-08-03,2012-03-21,0.0,DEATH
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,7.62217659137577,2011-08-03,2012-03-21,0.0,DEATH
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,4.402464065708419,2011-08-18,2011-12-29,0.0,DEATH
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,4.402464065708419,2011-08-18,2011-12-29,0.0,DEATH
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50,1.0,1.0,Time to Death (months),TIME2DTH,1.0,4.402464065708419,2011-08-18,2011-12-29,0.0,DEATH
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,11.104722792607802,2011-11-08,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,11.104722792607802,2011-11-08,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5,0.0,1.0,Time to Death (months),TIME2DTH,1.0,11.104722792607802,2011-11-08,2012-10-10,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,3.811088295687885,2012-03-27,2012-07-20,0.0,DEATH
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,3.811088295687885,2012-03-27,2012-07-20,0.0,DEATH
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,0,0.0,1.0,Time to Death (months),TIME2DTH,1.0,3.811088295687885,2012-03-27,2012-07-20,0.0,DEATH
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.626283367556468,2011-07-11,2012-04-28,0.0,DEATH
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.626283367556468,2011-07-11,2012-04-28,0.0,DEATH
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,0,1.0,1.0,Time to Death (months),TIME2DTH,1.0,9.626283367556468,2011-07-11,2012-04-28,0.0,DEATH
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,2.726899383983573,2011-10-03,2011-12-24,0.0,DEATH
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,2.726899383983573,2011-10-03,2011-12-24,0.0,DEATH
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,70,0.0,1.0,Time to Death (months),TIME2DTH,1.0,2.726899383983573,2011-10-03,2011-12-24,0.0,DEATH
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,9.100616016427105,2012-01-09,2012-10-11,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,9.100616016427105,2012-01-09,2012-10-11,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,80,1.0,1.0,Time to Death (months),TIME2DTH,1.0,9.100616016427105,2012-01-09,2012-10-11,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,0.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,8.24640657084189,2011-11-07,2012-07-14,0.0,DEATH
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,0.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,8.24640657084189,2011-11-07,2012-07-14,0.0,DEATH
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,60,0.0,1.0,Time to Death (months),TIME2DTH,1.0,8.24640657084189,2011-11-07,2012-07-14,0.0,DEATH
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,0.8870636550308009,2012-01-11,2012-02-06,0.0,DEATH
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,0.8870636550308009,2012-01-11,2012-02-06,0.0,DEATH
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months),TIME2DTH,1.0,0.8870636550308009,2012-01-11,2012-02-06,0.0,DEATH
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,7.885010266940451,2012-02-20,2012-10-16,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,7.885010266940451,2012-02-20,2012-10-16,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months),TIME2DTH,1.0,7.885010266940451,2012-02-20,2012-10-16,1.0,CENSORED AT TIME OF LAST FOLLOW-UP
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months) including subjects that w/d OS follow-up consent,TDTHSEN1,2.0,5.585215605749487,2011-11-22,2012-05-09,0.0,DEATH
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months) including Gem. Elaidate subjects that w/d OS follow-up consent,TDTHSEN2,3.0,5.585215605749487,2011-11-22,2012-05-09,0.0,DEATH
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,North America,1.0,US/Western Europe/Australia,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,N/A,1.0,1.0,Time to Death (months),TIME2DTH,1.0,5.585215605749487,2011-11-22,2012-05-09,0.0,DEATH
